Tango Therapeutics (TNGX) Price & Analysis

Compare

386 Followers

TNGX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.03 - $10.85

Previous CloseN/A

Volume187.94K

Average Volume (3M)1.70M

Market Cap

$772.15M

Enterprise Value$419.76M

Total Cash (Recent Filing)$181.21M

Total Debt (Recent Filing)$35.01M

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Nov 05, 2025

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding111,260,250

10 Day Avg. Volume1,353,525

30 Day Avg. Volume1,704,335

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.54

Enterprise Value/Revenue17.28

Enterprise Value/Gross Profit17.73

Enterprise Value/Ebitda-2.75

Forecast

1Y Price Target

$11.00

Price Target Upside61.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Analyst RatingsAnalysts have reiterated a Buy rating for Tango Therapeutics, Inc.'s stock.

Clinical TrialsThe combination of TNG462 and Revolution Medicines' inhibitors has shown enhanced antitumor activity compared to using either compound alone.

EarningsTango ended the quarter with $180.8 million in cash and marketable securities, providing an operational runway into the first quarter of 2027.

Bears Say

Clinical RisksRisks include negative clinical results with the lead asset, TNG462, and delays in advancing pipeline candidates into registrational trials.

CompetitionCompetitive risks exist, especially with respect to other clinical-stage PRMT5 inhibitors.

Tango Therapeutics News

Palo Alto upgraded, Li Auto downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

22d ago

Piper starts Tango Therapeutics with an Overweight on TNG462 potential

As previously reported, Piper Sandler initiated coverage of Tango Therapeutics (TNGX) with an Overweight rating and $11 price...

23d ago

TNGX

Tango Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Tango Therapeutics (TNGX) with an Overweight rating and $11 price target Published first...

23d ago

TNGX

Tango Therapeutics’ Chief Legal Officer Resigns

Tango Therapeutics ( ($TNGX) ) has issued an update. On August 21, 2025, Douglas Barry announced his resignation...

16d ago

TNGX

Tango Therapeutics Reports Q2 2025 Financial Results

Tango Therapeutics, Inc. ( ($TNGX) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

TNGX

Tango Therapeutics reports Q2 EPS (35c), consensus (34c)

Reports Q2 revenue $3.181M, consensus $6.7M. “TNG462 has the potential to be a best-in-class PRMT5 inhibitor for the...

1M ago

TNGX

Tango Therapeutics management to meet with Cantor Fitzgerald

Meetings to be held in San Francisco July 29-30 and in Denver on July 31 hosted by Cantor...

1M ago

TNGX

Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG462

Tango Therapeutics (TNGX) announced that the first patient has been dosed in the Phase 1/2 trial of TNG462...

3M ago

TNGX

Tango Therapeutics Approves Key Proposals at Annual Meeting

Tango Therapeutics ( ($TNGX) ) just unveiled an announcement. On June 5, 2025, Tango Therapeutics held its annual...

3M ago

TNGX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

TIL

ARMP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

SNY

ARMP

Tango Therapeutics announces first patient dosed in TNG456 Phase 1/2 trial

Tango Therapeutics (TNGX) announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in...

4M ago

TNGX

Tango Therapeutics: Promising Developments and Strategic Focus Justify Buy Rating

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Tango Therapeutics (TNGX – Research Report)....

4M ago

TNGX

Tango Therapeutics Extends Cash Runway Amid Clinical Progress

Tango Therapeutics, Inc. ( ($TNGX) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

TNGX

TNGX FAQ

What was Tango Therapeutics’s price range in the past 12 months?

Tango Therapeutics lowest stock price was $1.03 and its highest was $10.85 in the past 12 months.

What is Tango Therapeutics’s market cap?

Tango Therapeutics’s market cap is $772.15M.

When is Tango Therapeutics’s upcoming earnings report date?

Tango Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 56 days.

How were Tango Therapeutics’s earnings last quarter?

Tango Therapeutics released its earnings results on Aug 05, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.344 by -$0.006.

Is Tango Therapeutics overvalued?

According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tango Therapeutics pay dividends?

Tango Therapeutics does not currently pay dividends.

What is Tango Therapeutics’s EPS estimate?

Tango Therapeutics’s EPS estimate is -0.05.

How many shares outstanding does Tango Therapeutics have?

Tango Therapeutics has 111,260,250 shares outstanding.

What happened to Tango Therapeutics’s price movement after its last earnings report?

Tango Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.344. Following the earnings report the stock price went up 4.856%.

Which hedge fund is a major shareholder of Tango Therapeutics?

Currently, no hedge funds are holding shares in TNGX

Tango Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-76.09%

Trailing 12-Months

Asset Growth

-37.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics (TNGX) Earnings & Revenues

Historic Earnings Reports

TNGX Stock 12 Month Forecast

Average Price Target

$11.00

▲(61.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.66,7.147692307692308,7.635384615384615,8.123076923076923,8.61076923076923,9.098461538461539,9.586153846153847,10.073846153846155,10.561538461538461,11.04923076923077,11.536923076923078,12.024615384615384,12.512307692307694,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.66,6.993846153846154,7.327692307692308,7.661538461538462,7.995384615384616,8.329230769230769,8.663076923076924,8.996923076923077,9.330769230769231,9.664615384615384,9.99846153846154,10.332307692307692,10.666153846153847,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.66,6.916923076923077,7.173846153846154,7.430769230769231,7.687692307692307,7.944615384615385,8.201538461538462,8.458461538461538,8.715384615384615,8.972307692307693,9.22923076923077,9.486153846153847,9.743076923076924,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >